{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:51:13Z","timestamp":1776401473855,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105873","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:46:54Z","timestamp":1764078414000},"page":"105873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI"],"prefix":"10.1016","volume":"10","author":[{"given":"F.","family":"Martin-Moro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Browne-Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Diaz-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sanchez-Pina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garcia-Vela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Rodriguez-Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gonzalez De Villambrosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Del Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.D.","family":"Luzardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garcia-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lopez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bastos-Oreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2025.105873_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00277-020-03918-6","article-title":"RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group","volume":"99","author":"Bastos-Oreiro","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105873_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00428-022-03466-6","article-title":"Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities","volume":"482","author":"Song","year":"2023","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105873_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105873_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100750","article-title":"How I treat diffuse large B-cell lymphoma","volume":"8","author":"Melchardt","year":"2023","journal-title":"ESMO Open"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105873_bib5","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.105873_bib6","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105873_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib8","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3324\/haematol.2023.283097","article-title":"The International Prognostic Index: still relevant 30 years later","volume":"108","author":"LaCasce","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105873_bib9","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105873_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","article-title":"Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models","volume":"13","author":"Jelicic","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib12","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.14489","article-title":"Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of \u03b22-microglobulin yields a more accurate GELTAMO-IPI","volume":"176","author":"Montalb\u00e1n","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105873_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000621","article-title":"Prognostic value of baseline and interim positron emission tomography markers in diffuse large B-cell lymphoma patients: a real-world perspective","volume":"5","author":"Hatzl","year":"2021","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cyto.b.21863","article-title":"Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology","volume":"98","author":"Mart\u00edn-Moro","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105873_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000926","article-title":"Treatment strategies and prognostic factors in secondary central nervous system lymphoma: a multicenter study of 124 patients","volume":"7","author":"Treiber","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105873_bib16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/bloodadvances.2023011425","article-title":"Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105873_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100210","article-title":"Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis","volume":"6","author":"Oiwa","year":"2021","journal-title":"ESMO Open"},{"issue":"31","key":"10.1016\/j.esmoop.2025.105873_bib18","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non\u2013germinal center B-cell\u2013like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105873_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105873_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16263","article-title":"New prognosis score including absolute lymphocyte\/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)","volume":"188","author":"Bento","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105873_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105873_bib23","first-page":"2566","article-title":"How I treat older patients with DLBCL in the frontline setting","volume":"141","author":"Lugtenburg","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105873_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103965","article-title":"Safety of solid oncology drugs in older patients: a narrative review","volume":"9","author":"Rousseau","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105873_bib25","first-page":"8","article-title":"The mechanism of anemia in leukemia and malignant lymphoma","volume":"5","author":"Ross","year":"1954","journal-title":"BMQ"},{"key":"10.1016\/j.esmoop.2025.105873_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(60)90224-2","article-title":"Mechanisms of anemia in leukemia and malignant lymphoma","volume":"28","author":"Desforges","year":"1960","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105873_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.18208","article-title":"Novel prognostic predictor of haemoglobin\u2013platelet index in diffuse large B-cell lymphoma, not otherwise specified: anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells","volume":"198","author":"Taniguchi","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105873_bib28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ejh.12529","article-title":"The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients","volume":"95","author":"Troppan","year":"2015","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105873_bib30","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.6004\/jnccn.2015.0178","article-title":"Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI","volume":"13","author":"Melchardt","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105873_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood.V54.4.928.928","article-title":"Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas","volume":"54","author":"Ferraris","year":"1979","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105873_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bjc.1993.509","article-title":"Serum lactate dehydrogenase level as a prognostic factor in Hodgkin\u2019s disease","volume":"68","author":"Garc\u00eda","year":"1993","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105873_bib33","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1002\/cam4.1820","article-title":"Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy","volume":"7","author":"Feng","year":"2018","journal-title":"Cancer Med"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105873_bib34","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105873_bib35","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736","volume":"34","author":"Stephens","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105873_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.esmoop.2025.105873_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drudis.2008.11.001","article-title":"Beta2-microglobulin: emerging as a promising cancer therapeutic target","volume":"14","author":"Shi","year":"2009","journal-title":"Drug Discov Today"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105873_bib38","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2005.07.155","article-title":"Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin","volume":"23","author":"L\u00f3pez-Guillermo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105873_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5045\/br.2014.49.3.148","article-title":"Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor","volume":"49","author":"Yoo","year":"2014","journal-title":"Blood Res"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105873_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/bjc.1993.144","article-title":"Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin\u2019s lymphomas","volume":"67","author":"Johnson","year":"1993","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105873_bib41","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.1989.7.10.1518","article-title":"A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels","volume":"7","author":"Swan","year":"1989","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105873_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-021-00596-z","article-title":"Evolution of therapy for limited stage diffuse large B-cell lymphoma","volume":"12","author":"Rojek","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:50:38Z","timestamp":1766393438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017429"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105873","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105873"}}